Michael D Leise

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5177343/publications.pdf

Version: 2024-02-01

60 papers 2,095 citations

22 h-index

304602

233338 45 g-index

61 all docs

61 does citations

61 times ranked

3328 citing authors

#	Article	IF	CITATIONS
1	Drug-Induced Liver Injury. Mayo Clinic Proceedings, 2014, 89, 95-106.	1.4	325
2	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology, 2015, 61, 1880-1886.	3.6	166
3	A Revised Model for End-Stage Liver Disease Optimizes Prediction of Mortality Among Patients Awaiting Liver Transplantation. Gastroenterology, 2011, 140, 1952-1960.	0.6	131
4	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology, 2019, 157, 1253-1263.e2.	0.6	131
5	Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 859-860.	1.8	123
6	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology, 2019, 156, 1683-1692.e1.	0.6	121
7	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clinical Gastroenterology and Hepatology, 2017, 15, 767-775.e3.	2.4	112
8	Management of Hepatic Encephalopathy in the Hospital. Mayo Clinic Proceedings, 2014, 89, 241-253.	1.4	91
9	Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia–Related Epistaxis and Gastrointestinal Bleeding. Mayo Clinic Proceedings, 2018, 93, 155-166.	1.4	88
10	Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. Liver Transplantation, 2016, 22, 723-731.	1.3	59
11	High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data. World Journal of Gastroenterology, 2020, 26, 7693-7706.	1.4	59
12	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology, 2015, 62, 1004-1012.	3.6	54
13	Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation?. Gastroenterology Report, 2017, 5, 178-184.	0.6	49
14	Immunizations in Chronic Liver Disease: What Should be Done and What is the Evidence. Current Gastroenterology Reports, 2013, 15, 300.	1.1	48
15	Indwelling Tunneled Pleural Catheters forÂRefractory Hepatic Hydrothorax in Patients With Cirrhosis. Chest, 2019, 155, 546-553.	0.4	47
16	Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation. Liver Transplantation, 2014, 20, 687-697.	1.3	43
17	MELDâ€GRAILâ€Na: Glomerular Filtration Rate and Mortality on Liverâ€Transplant Waiting List. Hepatology, 2020, 71, 1766-1774.	3 . 6	40
18	lgG4-Associated Cholecystitis: Another Clue in the Diagnosis of Autoimmune Pancreatitis. Digestive Diseases and Sciences, 2011, 56, 1290-1294.	1.1	33

#	Article	IF	Citations
19	Patients Dismissed From the Hospital With a Diagnosis of Noncardiac Chest Pain: Cardiac Outcomes and Health Care Utilization. Mayo Clinic Proceedings, 2010, 85, 323-330.	1.4	30
20	Assessment of the spectrum of hepatic encephalopathy: A multicenter study. Liver Transplantation, 2018, 24, 587-594.	1.3	26
21	Endoscopic ultrasound-guided portal-systemic pressure gradient measurement. Endoscopy, 2014, 46, E654-E656.	1.0	23
22	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. Liver Cancer, 2017, 6, 126-136.	4.2	23
23	Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient. American Journal of Transplantation, 2021, 21, 2890-2894.	2.6	23
24	Hyponatremia in Cirrhosis: Implications for Liver Transplantation. Liver Transplantation, 2018, 24, 1612-1621.	1.3	22
25	Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National Readmissions Database. Annals of Translational Medicine, 2021, 9, 1052-1052.	0.7	19
26	Embolization of spontaneous portosystemic shunts for management of severe persistent hepatic encephalopathy. Hepatology, 2014, 59, 735-736.	3.6	18
27	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. Annals of Surgery, 2018, 268, 1043-1050.	2.1	18
28	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2020, 18, 974-983.	2.4	16
29	Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. Journal of Hepatology, 2021, 74, 873-880.	1.8	16
30	Endoscopic management of bile leaks after liver transplantation: An analysis of two high-volume transplant centers. United European Gastroenterology Journal, 2018, 6, 89-96.	1.6	15
31	Liver Transplantation Trends and Outcomes for Hereditary Hemorrhagic Telangiectasia in the United States. Transplantation, 2019, 103, 1418-1424.	0.5	15
32	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clinical Gastroenterology and Hepatology, 2022, 20, 183-193.	2.4	15
33	Incidence and Risk Factors Associated With 30-Day Readmission for Alcoholic Hepatitis. Journal of Clinical Gastroenterology, 2019, 53, 759-764.	1.1	11
34	Evaluation of liver stiffness with magnetic resonance elastography in patients with constrictive pericarditis: Preliminary findings. Journal of Magnetic Resonance Imaging, 2016, 44, 81-88.	1.9	10
35	Abdominal manifestations of hereditary hemorrhagic telangiectasia: a series of 333 patients over 15Âyears. Abdominal Radiology, 2019, 44, 2384-2391.	1.0	10
36	The Current Hepatic Encephalopathy Pipeline. Journal of Clinical and Experimental Hepatology, 2020, 10, 377-385.	0.4	9

3

#	Article	IF	CITATIONS
37	Clinical and histopathologic manifestations of solid organ transplantationâ€associated graftâ€versusâ€host disease involving the skin: A singleâ€center retrospective study. Journal of Cutaneous Pathology, 2018, 45, 817-823.	0.7	7
38	Drug therapy: Telaprevir. Hepatology, 2011, 54, 1463-1469.	3.6	6
39	Impact of Age on Outcomes in Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia. Advances in Hematology, 2018, 2018, 1-8.	0.6	6
40	Relationship between portopulmonary hypertension and splenectomy: Mayo Clinic experience and review of published works. Hepatology Research, 2018, 48, E340-E346.	1.8	5
41	Rifaximin in Hepatic Encephalopathy: Is an Ounce of Prevention Worth a Pretty Penny?. Gastroenterology, 2010, 139, 1416-1418.	0.6	4
42	Hyponatremia in the perioperative period: When and how to correct. Clinical Liver Disease, 2017, 9, 111-114.	1.0	4
43	Multicenter Experience using Ledipasvir/Sofosbuvir $\hat{A}\pm$ RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Annals of Hepatology, 2018, 17, 815-821.	0.6	4
44	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplantation Direct, 2021, 7, e635.	0.8	4
45	Association of $\hat{l}\pm 1$ Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation. Transplantation, 2021, 105, 1576-1584.	0.5	4
46	Hepatitis C nonresponders: Re-treat or retreat?. Hepatology, 2009, 50, 1307-1309.	3.6	2
47	Rifaximin for Episodic, Overt Hepatic Encephalopathy: The Data are Catching up to Clinical Practice, but Questions Remain. American Journal of Gastroenterology, 2014, 109, 598.	0.2	2
48	Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with directâ€acting antivirals for hepatitis C virus. Liver International, 2017, 37, 809-811.	1.9	2
49	75-Year-Old Man With Abdominal Pain and Weight Loss. Mayo Clinic Proceedings, 2008, 83, 1161-1164.	1.4	1
50	Living donor liver transplantation: Alive and well. Liver Transplantation, 2014, 20, 1290-1292.	1.3	1
51	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1814.	2.4	1
52	Latest Concepts in Inpatient Hepatic Encephalopathy Management. , 2018, , 77-97.		1
53	The Portosystemic Shunt Syndrome and Role of Shunt Embolization in the Management of Hepatic Encephalopathy. Current Hepatology Reports, 2018, 17, 218-224.	0.4	1
54	Early thoracentesis correlated with survival benefit in patients with spontaneous bacterial empyema. Digestive and Liver Disease, 2022, 54, 1015-1020.	0.4	1

#	Article	IF	CITATIONS
55	Complete endoscopic removal of a necrotic spleen (with video). Gastrointestinal Endoscopy, 2012, 75, 694-695.	0.5	O
56	Treatment of persistent/medically refractory covert hepatic encephalopathy with the molecular adsorbent recirculating system. Liver Transplantation, 2014, 20, 867-868.	1.3	0
57	64-Year-Old Woman With Diarrhea and Increased Abdominal Girth. Mayo Clinic Proceedings, 2015, 90, e35-e39.	1.4	O
58	Reply. Liver Transplantation, 2016, 22, 1736-1737.	1.3	0
59	Reply to: "Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence― Journal of Hepatology, 2017, 67, 1357.	1.8	O
60	Pseudoâ€Wilsonian Crisis in a ATP7B Heterozygote. Liver Transplantation, 2022, 28, 131-133.	1.3	0